Ubrolexin® - Clinical efficacy

The spectrum of activity of Ubrolexin® is broad, which includes the most important mastitis bacterial pathogens. It results from the synergistic activity of 2 narrow spectrum antibiotics, both having a focused bactericidal activity on a specific group of target pathogens.

 

The field efficacy of Ubrolexin® for the treatment of clinical mastitis in lactating cows was investigated in 2 international, multi-centre studies.

 

In one study, Ubrolexin® was compared to a 4th generation cephalosporin, cefquinome administered 3 times at 12 hours interval; in the second study, Ubrolexin® was compared to a 3rd generation cephalosporin, cefoperazone administered twice at 24 hours interval.

Sufficient data for analysis was available from a total of 491 cases on 192 farms in 3 countries (England, France and Germany). Clinical cases were of diverse aetiology representing both contagious and environmental pathogens.

 

In these studies, Ubrolexin® proved to be as efficacious as a 4th generation cephalosporin and significantly outperformed a 3rd generation cephalosporin.